Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial
References (32)
- et al.
The economic burden of low back pain: A review of studies published between 1996 and 2001
Best Pract Res Clin Rheumatol
(2002) - et al.
Postoperative opioid analgesia: Time for a reconsideration?
J Clin Anesth
(1996) - et al.
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
Lancet
(1999) - et al.
Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active- comparator-controlled clinical trial
Clin Ther
(1999) - et al.
The analgesic efficacy of valdecoxib vs. oxycodone/ acetaminophen after oral surgery
J Am Dent Assoc
(2002) - et al.
Prospective validation of clinically important changes in pain severity measured on a visual analog scale
Ann Emerg Med
(2001) - et al.
Clinical significance of reported changes in pain severity
Ann Emerg Med
(1996) - et al.
Medication use for low back pain in primary care
Spine
(1998) Back pain and sciatica
N Engl J Med
(1988)Drug therapy for back pain
Which drugs help which patients?
Spine
(1996)
Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty
Am J Ther
(2002)
Nonsteroidal anti-inflammatory drugs for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group
Spine
(2000)
The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs
Nonsteroidal antiinflammatory drugs—differences and similarities
N Engl J Med
(1991)
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
Cited by (63)
Delivery systems for the treatment of degenerated intervertebral discs
2015, Advanced Drug Delivery ReviewsCitation Excerpt :The basic mechanism of action consists of inhibition of cyclo-oxygenase activity [67]. Several different drugs based on non-steroidal molecules are being used to relieve back pain, such as diclofenac [68], ketoprofen [69], ibuprofen [70], naproxen, celebrex [71], valdecoxib [72] and etoricoxib [73]. NSAID treatment has been shown to be mainly efficient for short-term symptomatic relief in patients with acute back pain [74,75].
Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain
2023, BMC Musculoskeletal DisordersA Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain
2023, Research SquareEfficacy of pulsed electromagnetic field therapy on pain and physical function in patients with non-specific low back pain: a systematic review
2023, Wiener Medizinische WochenschriftPharmacotherapy for Spine-Related Pain in Older Adults
2022, Drugs and AgingBotulinum Neurotoxins and Chronic Low Back Pain
2022, Botulinum Toxin Treatment of Pain Disorders: Second Edition
The results of this study were presented in abstract and poster form at the 22nd Annual Scientific Meeting of the American Pain Society, March 20-23, 2003, Chicago, Illinois.
Copyright © 2004 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.